On November 6, Ge Longhui reported that wuhan hiteck biological pharma (300683.SZ) announced that the company recently received the《Drug Registration Certificate》of ketococaine injection approved and issued by the National Medical Products Administration. Ketococaine injection is suitable for peripheral arterial disease (intermittent claudication or rest pain), inner ear circulation disorders, and is a second-class national medical insurance variety.
Ketococaine and its metabolites improve blood rheological properties by reducing blood viscosity. In patients with chronic peripheral arterial disease, it can increase blood flow in the affected microcirculation and improve tissue oxygen levels. It improves blood rheological properties in a dose-dependent manner, reducing blood viscosity and increasing red blood cell deformability. It also enhances white blood cell deformability, inhibits neutrophil adhesion and activation.
The ketococaine injection approved by the company is classified as Class 3 for chemical drugs in the application for registration, considered to have passed the generic drug consistency evaluation. IQVIA database shows that the hospital procurement amount of this pharmaceutical in 2023 was RMB 1144.72 million.
